|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
29 April 2024 |
|
Main ID: |
NCT02980640 |
|
Date of registration:
|
23/11/2016 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Swiss Multiple Sclerosis Registry
SMSR |
|
Scientific title:
|
Swiss Multiple Sclerosis Registry |
|
Date of first enrolment:
|
June 2016 |
|
Target sample size:
|
10000 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/ct2/show/NCT02980640 |
|
Study type:
|
Observational [Patient Registry] |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Switzerland
| | | | | | | |
|
Contacts
|
|
Name:
|
Milo Puhan, MD PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of Zurich |
|
|
Name:
|
Viktor von Wyl, PhD |
|
Address:
|
|
|
Telephone:
|
++41 (0)44 634 6380 |
|
Email:
|
viktor.vonwyl@uzh.ch |
|
Affiliation:
|
|
|
|
Name:
|
Milo Puhan, MD PhD |
|
Address:
|
|
|
Telephone:
|
++41 (0)44 634 4610 |
|
Email:
|
miloalan.puhan@uzh.ch |
|
Affiliation:
|
|
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Persons with a confirmed Multiple Sclerosis Diagnosis
- 18 years and older
- Living in Switzerland or receiving MS care in Switzerland
Exclusion Criteria:
- Younger than 18 years
- Not living in Switzerland and not receiving MS care in Switzerland
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Multiple Sclerosis
|
|
Primary Outcome(s)
|
|
Change in Health-Related Quality of Life
[Time Frame: Baseline; 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 months]
|
|
Change in Self-Assessment of Health Status
[Time Frame: Baseline; 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 months]
|
|
Secondary Outcome(s)
|
|
Occurrence of MS Symptoms
[Time Frame: Baseline; 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 months]
|
|
Occurrence of Adverse Drug Effects
[Time Frame: Baseline; 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 months]
|
|
Occurrence of MS Relapse
[Time Frame: Baseline; 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 months]
|
|
Secondary ID(s)
|
|
PB_2016-00894
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|